Zeiss to Showcase New Digital Technologies at ASCRS
Zeiss Medical Technology will celebrate the adoption of digital cataract solutions and showcase newly available refractive treatment technology at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25–27 in Los Angeles.
Zeiss marks a major milestone in the US with more than 2 million digitally planned cases using the Zeiss Veracity Surgery Planner, a digital planning solution for cataract surgery.
“The digital era continues to grow at a rapid pace. Ophthalmologists are increasingly realizing the significant benefits of using digital workflows as the backbone of their medical practices,” Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at Zeiss Medical Technology, said in a company news release. “Zeiss has much to celebrate at ASCRS this year, including our continued US leadership in digital innovation and ongoing commitment to improving patient care across both the cataract and refractive markets.”
Additionally, the Zeiss Refractive Workflow will showcase for the first time both the VISUMAX 800 with SMILE pro from Zeiss, and the MEL 90 from Zeiss. Also, for the first time, DORC and FCI, both Zeiss companies, are set to present their portfolio of cataract surgical solutions in the Zeiss booth, showcasing the extended benefits of ZEISS’s surgical portfolio.
At ASCRS, Zeiss will celebrate the milestone of 2 million digitally planned cases with its cloud-based Zeiss Veracity Surgery Planner. A recent study showed that with the Zeiss Cataract Workflow powered by Zeiss Veracity Surgery Planner, surgeons and staff can save up to 60% of their time per eye compared to traditional paper planning.[2]
In addition to proven efficiency gains, new research abstracts presented at this year’s ASCRS showcase refractive accuracy and clinical outcomes when adopting the Zeiss Cataract Workflow:
- Steven C. Schallhorn, MD, ABO, will present a clear benefit of reducing postoperative astigmatism by implanting toric IOLs in patients with lower preoperative corneal astigmatism, leveraging cataract outcomes obtained from VERACITY Surgery Planner’s database of 50,850 eyes with preoperative corneal astigmatism between 0.75D and 1.50D.
- Luke Rebenitsch, MD, ABO, will present a comparison of refractive outcomes in a large cohort of 49,057 eyes undergoing cataract surgery with toric IOL implantation where the use of the ZEISS CALLISTO eye system resulted in significant improvements in terms of post-op refractive outcomes compared to a manual marking approach.
- Kamran M. Riaz, MD, ABO, will present an analysis of the refractive accuracy of two biometers in a cohort of 222 eyes with prior laser vision correction and implantation of toric multifocal IOLs, highlighting the significantly better performance of total keratometry with the IOLMaster 700.
Zeiss also announced the availability of both the Zeiss Veracity Visumax 800 and Zeiss MEL 90. For the first time, the Zeiss MEL 90 will be showcased in the US at ASCRS, extending Zeiss' LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism.
Zeiss will showcase for the first time together in the booth key solutions from DORC and FCI. This will feature the DORC EVA NEXUS surgical system for cataract and phaco-vitrectomy surgeries. It will also include the DORC VisionBlue anterior stain, a trusted choice in more than 10 million cataract surgeries since its introduction. As the only FDA-approved trypan blue stain for anterior applications, it is also authorized for staining Descemet’s membrane and trabecular meshwork. Additionally, the Zeiss booth will feature the FDA-approved Eyejet 20C from Morcher, built on the preloaded Eyejet system and designed to prevent toric IOLs rotation, providing maximum toric benefits.
Zeiss will showcase its latest offerings at booth #1501.